Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CD3/CLL1 TDB, anti-CD3/anti-CLL1 bispecific T-cell engager (Genentech) |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), CLL-1 modulators(C-Type lectin domain family 12 member A modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Discovery | US | - |